Picamilon in stage I and II chronic cerebral ischemia: open comparative study
Observational study · 2025
- What was studied
- 100 enrolled; 94 in per-protocol efficacy analysis; stage I and II groups initially 50 each
- Main finding
- In the 2025 open Picamilon comparison, MoCA increased from 24.9 to 28.3 in stage I disease and from 20.9 to 25.9 in stage II disease. Sleep and symptom scores also improved; there was no placebo or untreated group.
MoCA score, mean ± SD · Stage I: 24.9 ± 3.78 → 26.5 ± 2.77 → 28.3 ± 2.18; stage II: 20.9 ± 4.79 → 24.6 ± 3.64 → 25.9 ± 3.88 · Within-stage values; not randomized disease-stage comparison · Baseline → end of treatment → 45-day follow-up
Reported findings and study design
In the 2025 open Picamilon comparison, MoCA increased from 24.9 to 28.3 in stage I disease and from 20.9 to 25.9 in stage II disease. Sleep and symptom scores also improved; there was no placebo or untreated group.
100 enrolled: stage I 50 (oral 25; sequential injection/oral 25), stage II 50. Efficacy analyzed in 94 completers; all 100 in safety. Treatment 60 days (I) or 70 days (II); follow-up 45 days later.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| MoCA score, mean ± SD | Stage I: 24.9 ± 3.78 → 26.5 ± 2.77 → 28.3 ± 2.18; stage II: 20.9 ± 4.79 → 24.6 ± 3.64 → 25.9 ± 3.88 | Within-stage values; not randomized disease-stage comparison · Baseline → end of treatment → 45-day follow-up |
| Sleep score, mean ± SD | Stage I: 19.7 ± 3.77 → 22.7 ± 3.46 → 24.3 ± 3.06; stage II: 18.5 ± 4.01 → 21.8 ± 3.61 → 22.8 ± 3.01 | Levin subjective questionnaire; higher is better · Same visits |
| Adverse events | 4/50 stage I; 4/50 stage II; none serious or causing discontinuation | All 100 enrolled patients in safety analysis · Treatment period |
| Attrition | 6/100 did not complete; efficacy used 94 completers | Withdrawals reported unrelated to adverse reactions |
Cognition, autonomic symptoms, neurological symptoms and sleep — Tables 3–6
| Measure / group | Baseline mean (SD) | End-treatment mean (SD) | Follow-up mean (SD) | Within-group tests |
|---|---|---|---|---|
| MoCA · stage I | 24.9 (3.78) | 26.5 (2.77) | 28.3 (2.18) | baseline→end p=0.022; end→follow-up p<0.0001 |
| MoCA · stage I oral | 23.8 (4.44) | 25.8 (3.37) | Not separately listed | p=0.065 |
| MoCA · stage I sequential | 26.1 (2.9) | 27.2 (1.73) | Not separately listed | p=0.161 |
| MoCA · stage II | 20.9 (4.79) | 24.6 (3.64) | 25.9 (3.88) | p<0.0001; p=0.0006 |
| Vein autonomic scale · I | 26.7 (14.0) | 17.3 (12.2) | Not measured | p<0.0001 |
| Vein scale · I oral | 29 (14.9) | 19.2 (12.3) | Not measured | p=0.0004 |
| Vein scale · I sequential | 24.1 (12.9) | 15.2 (12) | Not measured | p=0.007 |
| Vein scale · II | 25.3 (13.1) | 18.3 (15.2) | Not measured | p=0.0014 |
| Fedin neurological scale · I | 11.9 (8.3) | 6 (6.1) | 2.77 (4.43) | p<0.0001; p<0.0001 |
| Fedin · I oral | 12.4 (8.12) | 5.61 (5.12) | Not separately listed | p=0.0006 |
| Fedin · I sequential | 11.3 (8.65) | 6.43 (7.12) | Not separately listed | p=0.004 |
| Fedin · II | 17.4 (9.34) | 8.06 (6.84) | 5.31 (5.71) | p<0.0001; p=0.0002 |
| Levin sleep · I | 19.7 (3.77) | 22.7 (3.46) | 24.3 (3.06) | p<0.0001; p=0.0002 |
| Levin sleep · I oral | 20.0 (4.37) | 23.7 (3.72) | Not separately listed | baseline→end p=0.0026 |
| Levin sleep · I sequential | 19.3 (3.04) | 21.5 (2.80) | Not separately listed | p=0.0051 |
| Levin sleep · II | 18.5 (4.01) | 21.8 (3.61) | 22.8 (3.01) | p<0.0001; p=0.009 |
Tables transcribed from the publisher PDF text, printed pp.103–105; visual page inspection unavailable. Stage I visit 2 sleep: 20.7 (3.19), oral 20.9 (3.63), sequential 20.4 (2.69); stage II 19.3 (4.05). MoCA/Levin higher is better; Vein/Fedin lower is better. Subgroup MoCA changes were not significant.
Arginine biomarkers — original Table 10
| Measure / stage | Baseline median (Q1; Q3) | End-treatment median (Q1; Q3) | Paired p |
|---|---|---|---|
| ADMA · I (n=37) | 159 (146; 167) | 135 (108; 157) | 0.001 |
| SDMA · I | 179 (163; 212) | 179 (129; 199) | 0.104 |
| ADMA/MMA · I | 14.5 (13.4; 15.3) | 12 (11.1; 12.4) | <0.001 |
| (ADMA+SDMA)/MMA · I | 31.4 (28.3; 32.8) | 26.3 (23.4; 29.6) | <0.001 |
| SDMA/MMA · I | 17.3 (13.9; 18) | 14.2 (12.2; 17.4) | 0.002 |
| ADMA · II (n=42) | 167 (148.5; 177) | 138 (115.5; 152) | <0.001 |
| SDMA · II | 195 (173; 234) | 186 (148.5; 233) | 0.037 |
| ADMA/MMA · II | 14.3 (13.15; 15.3) | 11.2 (10.85; 12) | <0.001 |
| (ADMA+SDMA)/MMA · II | 33.3 (28.65; 35.8) | 26.4 (23.2; 31.5) | <0.001 |
| SDMA/MMA · II | 18.1 (14.9; 20.25) | 15.7 (12.15; 19.25) | 0.002 |
Publisher PDF text, printed p.106. ADMA/SDMA concentrations in ng/mL; ratios unitless. Biomarker subset 79, not the full 100. Stage I SDMA did not significantly change. Other vascular tables remain to be visually checked before full transcription.
This paper may overlap with the 2024 Picamilon reports; their participants must not be added as independent cohorts. Active-treatment improvements and blood markers do not establish prevention of stroke or cardiovascular events.
Source for these results ↗ · Reviewed 2026-11-01
Study limitations and source details
Study limitations
- No untreated or placebo group.
- Shared investigators, protocols and cohort characteristics suggest possible overlap with the 2024 reports; this is an inference, not confirmed participant identity.
- The three reports list 44, 50 and 100 participants. The extent of overlap is unknown.
Related publications may describe some of the same participants or experiments.
Source details
Publisher HTML article
Original publisher PDF methods and Tables 3–7, 10 text reviewed; visual table verification and complete Doppler-table transcription remain open
Methods and results
Sources checked
Citation
A. B. Danilov, N. N. Shindryaeva, I. V. Borodulina, T. D. Lunev. Picamilon in stage I and II chronic cerebral ischemia: open comparative study Consilium Medicum. 2025;27(2)
Study source ↗ · DOI 10.26442/20751753.2025.2.203195 · Bibliography entry · Link to this summary